The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on June 28 to discuss whether COVID-19 vaccines should be modified to account for new and different variant strains ahead of a potential fall/winter surge in the U.S. Moderna has released early study data of a new, bivalent COVID-19 vaccine (i.e., a vaccine that includes two different strains of mRNA to train the immune system to respond to a wider range of variants). The vaccine reportedly generated higher antibody responses than the previous Moderna booster including against the Omicron variants. Moderna stated that it plans to submit this interim analysis to the FDA for review ahead of a probable fall booster campaign. Pfizer/BioNTech announced in January 2022 that they would be testing their own Omicron-specific vaccine although they have not yet released any data.